Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Antoine

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Pharmacy and Pharmacology|August 2, 2001
Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ringS Boverie, M H Antoine, P de Tullio, et al.
Diabetologia|February 3, 1998
Verapamil, a phenylalkylamine Ca2+ channel blocker, inhibits ATP-sensitive K+ channels in insulin-secreting cells from ratsP Lebrun, M H Antoine, R Ouedraogo, et al.
International Journal of Pharmaceutics|March 1, 2021
Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in miceS Chraibi, R Rosière, E De Prez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 10, 2021
Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancerS Chraibi, R Rosière, E De Prez, et al.
Journal of Medicinal Chemistry|October 15, 1993
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?B Pirotte, P de Tullio, P Lebrun, et al.
Revue Medicale De Bruxelles|May 24, 2008
[Experimental nephrology unit: overview and research projects]M Deschodt-Lanckman, M H Antoine, F Debelle, et al.
British Journal of Pharmacology|September 21, 2001
Synthesis and characterization of a quinolinonic compound activating ATP-sensitive K(+) channels in endocrine and smooth muscle tissuesB Becker, M H Antoine, Q A Nguyen, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Activation of ATP-dependent K+ channels and inhibition of insulin release: effect of BPDZ 62P Lebrun, M H Antoine, R Ouedraogo, et al.
Journal of Medicinal Chemistry|July 27, 2001
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activityF Somers, R Ouedraogo, M H Antoine, et al.
Bioorganic & Medicinal Chemistry|September 11, 1999
Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2-butylamino)-4H- and 3-(3-methyl-2-butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openersS Khelili, P de Tullio, P Lebrun, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Pharmacy and Pharmacology|August 2, 2001
Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ringS Boverie, M H Antoine, P de Tullio, et al.
Diabetologia|February 3, 1998
Verapamil, a phenylalkylamine Ca2+ channel blocker, inhibits ATP-sensitive K+ channels in insulin-secreting cells from ratsP Lebrun, M H Antoine, R Ouedraogo, et al.
International Journal of Pharmaceutics|March 1, 2021
Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in miceS Chraibi, R Rosière, E De Prez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 10, 2021
Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancerS Chraibi, R Rosière, E De Prez, et al.
Journal of Medicinal Chemistry|October 15, 1993
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?B Pirotte, P de Tullio, P Lebrun, et al.
Revue Medicale De Bruxelles|May 24, 2008
[Experimental nephrology unit: overview and research projects]M Deschodt-Lanckman, M H Antoine, F Debelle, et al.
British Journal of Pharmacology|September 21, 2001
Synthesis and characterization of a quinolinonic compound activating ATP-sensitive K(+) channels in endocrine and smooth muscle tissuesB Becker, M H Antoine, Q A Nguyen, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Activation of ATP-dependent K+ channels and inhibition of insulin release: effect of BPDZ 62P Lebrun, M H Antoine, R Ouedraogo, et al.
Journal of Medicinal Chemistry|July 27, 2001
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activityF Somers, R Ouedraogo, M H Antoine, et al.
Bioorganic & Medicinal Chemistry|September 11, 1999
Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2-butylamino)-4H- and 3-(3-methyl-2-butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openersS Khelili, P de Tullio, P Lebrun, et al.
Pageof 4